$CNXU

Conexeu Sciences Inc.

CIK:0002066836|SEC Filings

Condensed Interim Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2026	Jul. 31, 2025	Jul. 31, 2026	Jul. 31, 2025
OPERATING EXPENSES
Advertising and promotion	$ 105,956	$ 21,288	$ 126,665	$ 48,503
Depreciation and amortization	5,435	6,640	23,296	10,604
Bank charges	3,714	1,474	9,390	3,132
Business development	1,227,253	52,166	1,410,010	146,386
Consulting	3,784,642	465,361	5,446,548	661,957
Filing and listing fees	100,430	9,363	125,689	9,513
Insurance	164,457	4,148	172,857	4,148
Investor relations	26,360	0	33,042	0
Management and directors' salaries and fees - related parties	1,512,974	457,231	2,848,679	750,033
Office and general administrative	34,647	1,282	58,490	7,632
Professional fees	216,588	114,872	809,307	216,219
Regulatory fees	235,505	29,134	328,149	29,134
Research and development	270,412	134,662	399,578	200,795
Total operating expenses	7,688,373	1,297,621	11,791,700	2,088,056
LOSS FROM OPERATIONS	(7,688,373)	(1,297,621)	(11,791,700)	(2,088,056)
OTHER INCOME (EXPENSES)
Gain on conversion of payables	0	0	0	43,176
Write-off of deferred offering costs	(73,169)	0	(73,169)	0
Interest income	34,214	386	129,800	386
Interest expense	0	43	0	(4,949)
Foreign exchange gain (loss)	1,677	(1,378)	(13,688)	2,759
Total other income (expenses)	(37,278)	(949)	42,943	41,372
LOSS BEFORE TAXES	(7,725,651)	(1,298,570)	(11,748,757)	(2,046,684)
Income tax benefit (expense)	0	0	0	0
NET LOSS	$ (7,725,651)	$ (1,298,570)	$ (11,748,757)	$ (2,046,684)
Net loss per common share
Net loss per common share, basic	$ (0.29)	$ (0.09)	$ (0.52)	$ (0.19)
Net loss per common share, diluted	$ (0.29)	$ (0.09)	$ (0.52)	$ (0.19)
Weighted average of common shares outstanding
Weighted average of common shares outstanding, basic	26,971,608	14,101,995	22,725,622	10,861,432
Weighted average of common shares outstanding, diluted	26,971,608	14,101,995	22,725,622	10,861,432

Condensed Interim Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Cash flows from operating activities
Net loss	$ (11,748,757)	$ (2,046,684)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization expense	12,888	5,477
Depreciation expense	10,408	5,127
Fixed asset, disposed	2,740	0
Gain on conversion of payables	0	(43,176)
Warrants issued for services	0	263,453
Warrants issued to related parties	0	149,374
Options issued for services	1,493,977	0
Shares issued for services	3,081,289	480,496
Loss on write-off of offering costs	73,169	0
Operating lease - right of use	9,841	0
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	524,865	1,785
Accounts payable and accrued liabilities - related parties	45,374	0
Interest receivable	(2,426)	0
Taxes receivable	3,037	(11,962)
Wages payable	(76,000)	0
Prepaid expenses	(3,524,559)	(42,300)
Security deposit	(18,475)	0
Lease liability	(9,000)	0
Liability to be settle by shares	22,350	0
Net cash used in operating activities	(10,099,279)	(1,238,410)
Cash flow from investing activities
Purchase of fixed assets	(76,229)	(18,668)
Change in convertible note receivables	(2)	0
Loan receivable	0	(40,386)
Net cash used in investing activities	(76,231)	(59,054)
Cash flow from financing activities
Receivable form issuance of private placement shares	2,000,000	0
Repayments on due to shareholders	0	(4,189)
Proceeds for shares issued under the warrant inducement program	2,720,561	0
Proceeds for warrants issued under the warrant inducement program	5,526	0
Proceeds received for performance warrants exercised	1,750	0
Proceeds from private placement, net of issuance costs	2,943,351	2,018,413
Repayments on insurance funding agreement	(92,187)	0
Repayment of loan payable	0	(94,206)
Offering costs paid for future offering	(30,992)	(99,627)
Net cash provided by financing activities	7,548,009	1,820,391
Effect of exchange rate changes on cash	2,997	(4,415)
Increase in cash, cash equivalents and restricted cash	(2,627,501)	522,927
Cash, cash equivalents and restricted cash at beginning of period	4,834,120	314,616
Cash, cash equivalents and restricted cash at end of period	2,209,616	833,128
Supplemental cash flow information
Cash paid for interest	0	17,547
Cash paid for taxes	0	0
Non-cash investing and financing activities
Shares issued for prepaid expenses	0	353,262
Warrants issued for services to be expensed	0	218,724
Investment	71,328	0
Prepaid insurance from funding agreement	469,785	0
New right of use addition	81,482	0
Shares issued for conversion of payables	$ 0	$ 122,897

Condensed Balance Sheets - USD ($)	Jul. 31, 2026	Oct. 31, 2025
CURRENT ASSETS
Cash and cash equivalents	$ 1,971,408	$ 4,808,965
Restricted cash	238,208	25,155
Share subscription receivable	0	2,000,000
Tax receivable	0	3,037
Interest receivable	2,426	0
Convertible note receivable	0	71,326
Prepaid expenses	4,544,274	549,930
TOTAL CURRENT ASSETS	6,756,316	7,458,413
NON-CURRENT ASSETS
Deferred offering costs	0	42,177
Investment, at cost	71,328	0
Security deposit	18,475	0
Operating lease - Right of Use, net of accumulated amortization of $9,841 and $0, respectively	71,641	0
Fixed assets, net of accumulated depreciation of $16,195 and $7,431, respectively	74,318	11,237
Patent, net of accumulated amortization of $22,707 and $9,819, respectively	163,996	176,884
TOTAL ASSETS	7,156,074	7,688,711
CURRENT LIABILITIES
Accounts payable and accrued liabilities	784,158	256,296
Accounts payable and accrued liabilities - related parties	45,374	0
Wages payable	0	76,000
Lease liability	39,249	0
Insurance funding agreement	377,598	0
Liabilities to be settled with shares	22,350	0
Due to shareholders	3,722	3,722
TOTAL CURRENT LIABILITIES	1,272,451	336,018
LONG-TERM LIABILITIES
Non-current lease liability	33,233	0
TOTAL LIABILITIES	1,305,684	336,018
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred Stock, par value $0.001, 50,000,000 shares authorized, 0 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively	0	0
Common Stock, par value $0.001, 250,000,000 shares authorized, 27,397,164 and 18,906,066 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively	27,397	18,906
Additional paid-in capital	22,093,270	11,855,307
Accumulated deficit	(16,270,277)	(4,521,520)
TOTAL SHAREHOLDERS' EQUITY	5,850,390	7,352,693
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 7,156,074	$ 7,688,711